INTRODUCTION

Detection of incidental renal masses is increasing because of the widespread use of imaging studies. Over two thirds of renal masses noted incidentally on abdominal CT-scans for non-urological indications are most likely to be renal cell carcinoma (RCC)(1, 4, 8, 10, 15). Needle biopsy has the potential to decrease the number of unnecessary treatments for benign pathological findings(15). Traditionally, tissue sampling of renal lesions has been performed via the percutaneous approach or laparoscopically, in order to characterize radiographically indeterminate lesions, confirm malignancy in not surgical candidates or to guide preoperative planning(1, 4, 10, 15).

Few studies addressed this issue and it remains unclear if endoscopic ultrasound (EUS) may have a role in the diagnostic work-up evaluation for RCC(4). It has been previously demonstrated the utility of EUS to biopsy the prostate and adrenal gland and to evaluate metastatic renal tumors(10). There are few data that describe the safety and feasibility of EUS for biopsy of the kidney.

The aim of this study is to describe the largest single-center case series in the literature and review our initial experience regarding feasibility and outcome of echoendoscopic fine needle aspiration of kidney tumors.

METHODS

This retrospective study protocol evaluate the usefulness of echoendoscopic ultrasonography with fine needle aspiration (EUS FNA) of renal masses according to recommended guidelines. Written informed consent approved by the Institutional Review Board at Sao Paulo Medical School was obtained before each procedure. EUS guided renal biopsies were performed by a single endosonographer with over 10 years of EUS experience.

All patients had abdominal evaluation with computerized tomography with endovenous contrast or magnetic resonance with gadolinium before the procedure. EUS guided renal biopsies were performed by a single endosonographer with over 10 years of EUS experience.

Survey for bleeding was performed even in patients with no history of bleeding. Relevant history,
platelet count, international normalized ratio and partial thromboplastin time within 1 month of biopsy. Patients were advised to discontinue aspirin and nonsteroidal antiinflammatory drugs 7 to 10 days before the procedure and to stop warfarin in time to establish an acceptable international normalized ratio, which usually requires 5 days. Continuous heparin was stopped 4 hours before the procedure.

Sectorial EUS (echoendoscope GF-UCT 140, Olympus, America Corp., Melville, NY) sectorial array probe with 0.5 MHz, reaching 12.5 cm was used in this study. The anatomic location of both kidneys allows endosonographic imaging and direct needle access for tissue acquisition\(^\text{11}\). The echoendoscope used reaches 12.5 cm or 7.5 MHz and with the movement of the probe within the duodenum or stomach, this range is sufficient to visualize both kidneys. The right kidney may be approached from the second portion of the duodenum with the EUS transducer rotated laterally. The left kidney may be approached from within the body of the stomach with the EUS transducer facing posterolaterally. The proximity of the EUS tip to the kidney from within the gastrointestinal lumen allows precise location and accurate access for tissue acquisition. Schematization of the echoendoscope, EUS areas of interest for kidney approach (green duodenal area for the right kidney and yellow stomach area for the left kidney), appropriate visualization of the kidney (cortex and medulla), EUS visualization of tumor with needle insertion and aspiration and finally, cytologic aspirate is represented in Figure I. In all cases, three passes with a 22G needle (Cook Medical) were performed for echoendoscopic fine needle aspiration of renal tumors for adequate cytologic sampling. EUS FNA was performed on an outpatient basis. Only in one case, the procedure was done during hospitalization (EUS FNA of bilateral renal masses).

Data collected included patient age and sex, clinical indication of renal biopsy, location and size of renal tumor, EUS FNA cytology, final pathological findings, surgery results, postoperative hospital stay, complications, and clinical follow-up. The criterion standard for diagnosis of any renal mass was histopathological findings from surgical resection. Nephron-sparing procedures were performed depending on tumor site, location and intraoperative evaluation. Cytologic analysis was compared with final pathological results.

Histopathological evaluation of the FNA was performed after hematoxylin-eosin staining. Histochemical techniques for surgical specimens included Hale and PAS staining. Immunohistochemistry for the antibodies used for renal cell tumors included pancytokeratin, CK7, CK20, vimentin, EMA, CD10, CD117 (c-kit), E-cadherin, WT1 and HMB-45, desmin and SMA.

RESULTS

Ten EUS FNA of renal masses were performed in nine male patients (mean age 56.5 years, median age 54.7 years). The procedure was on the right kidney (n = 4), on the left kidney (n = 4) and bilaterally in one. Tumors involved the upper pole (n = 3), the lower pole (n = 2), the mesorenal region (n = 3) and was considered a large mass (more than one kidney region involved) in two cases. Median tumor diameter was 55 mm (ranging 13 mm to 160 mm).

Clinical indication for CT or MRI abdominal evaluation was macroscopic hematuria (n = 3), flank pain (n = 1) and abdominal mass (n = 2). In the three remaining cases, renal tumors were incidentally discovered. Indication for renal mass biopsy according to clinical guidelines were small renal mass (n = 4), suspicion of lymphoma (n = 1), suspicion of metastasis (n = 1), suspicion of oncocytoma (n = 1) in the case of bilateral EUS renal FNA, to distinguish between RCC and nephroblastoma in a young adult patient with renal mass and metastatic disease in one case and finally for histologic subtype analysis to predict response to immunotherapy in a RCC case with brain metastasis. The clinical features are summarized in Table 1.

Final EUS FNA cytology was available in nine of the 10 attempted biopsies. One biopsy failure occurred in a case of a small posterior kidney tumor (biopsy number 4, Table 1). The renal hilum was visualized across the tract of the EUS FNA and although one pass with 22G needle was attempted, no more attempts were performed and tissue was insufficient. In all other cases, an accurate biopsy was performed which revealed clear cell RCC (n = 5), papillary RCC in two aspirates (bilateral tumors in the same patient), nephroblastoma (n = 1) and pulmonary carcinoma (n = 1).

Contact was done via telephone to determine any complication after the biopsy. No complications were reported. Patients with RCC were followed according to the guidelines of European Association of Urology (available on http://www.uroweb.org/guidelines/online-guidelines).
Moura RN, Lopes RI, Srougi MF, Dall'Oglio MF, Sakai P, Artifon ELA.

Initial experience with endoscopic ultrasound-guided fine needle aspiration of renal masses: indications, applications and limitations

More than 200,000 new cases of kidney cancer are diagnosed annually, with more than 100,000 related deaths per year worldwide. RCC accounts for 3% of all adult malignancies and is increasing at a rate of 2.5% per year.

An enhancing renal neoplasm on CT or MRI has been considered by most urologists to be a sufficient indication for surgery because about 80% of such lesions prove to be RCC. Currently, if local experience is sufficient and the biopsy result has the potential to impact treatment decisions, urologists should consider increasing the use of core biopsy and FNA to better characterize suspicious renal masses preoperatively. The advantages of a biopsy in these cases are the potential to decrease unnecessary treatment of small renal masses and better selection of tumors for active surveillance and minimally invasive ablative therapies.

The role of needle core biopsy and FNA of renal masses is primarily to rule out non renal cell primary tumors (metastasis and lymphoma) or benign conditions (abscess), which may not require surgery. Biopsy has also been used to confirm the diagnosis and the histological subtype of a renal primary lesion in patients with disseminated metastasis or unresectable retroperitoneal mass. In metastatic RCC, there is evidence that patients with clear cell subtype histology are more likely to benefit from adjuvant immunotherapy following cytoreductive nephrectomy. A role for biopsy in the new target therapies demonstrate different response rates with different RCC subtypes.

FNA with immunocytochemistry analysis can help distinguish between RCC and oncocytomas. Even though RCC may be present in as many as 18% of oncocytomas, a EUS FNA showing oncocytoma, might allow surveillance for a renal lesion, especially if the patient prefers conservative management.

Percutaneous renal mass biopsy must not be performed routinely for renal lesions less than 40 mm but it should be indicated for incompletely accurate renal imaging diagnosis after a full imaging evaluation. Almost in 30% of the selected patients, a surgical procedure became no mandatory after renal biopsy was low. In the current study, there were no complications reported.

Preoperative biopsy of renal masses should be indicated only in selected cases. Good results for EUS FNA of selected renal tumors were observed in this study. Our overall technical success rate of EUS-guided FNA was 90%, which is within the range previously reported.

The risk of complications associated with EUS FNA ranges from less than 1-6%. Tracheal suction (5%), vomiting (0.3%), aspiration (0.3%), esophageal perforation and death (less than 0.06%) are reported complications of EUS. Tumor seeding is a potential unlikely complication of EUS FNA with few cases reported. The incidence of hemorrhage after biopsy was low (1%). In the current study, there were no complications reported.

Preoperative biopsy of renal masses should be indicated only in selected cases. Good results for EUS FNA of selected renal tumors were observed in this study. Our overall technical success rate of EUS-guided FNA was 90%, which is within the range previously reported.

The cause of failed procedure was due to the posterior aspect of this tumor and the smaller needle-tumor distance. In this patient, it appears to us that a computerized tomography guided posterior renal biopsy should be more appropriate. Some renal masses may

### TABLE 1. Echoendoscopic ultrasonography with fine needle aspiration (EUS-FNA) renal biopsy

<table>
<thead>
<tr>
<th>Biopsy number</th>
<th>Age/ Sex</th>
<th>Clinical Picture</th>
<th>Indication</th>
<th>Kidney (side)</th>
<th>Kidney pole</th>
<th>Diameter (cm)</th>
<th>Final citology</th>
<th>Surgery</th>
<th>Histology</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>61/M</td>
<td>Macroscopic hematuria</td>
<td>Suspicion of lymphoma</td>
<td>R</td>
<td>Large mass</td>
<td>16</td>
<td>Clear cell RCC</td>
<td>No</td>
<td>-</td>
<td>DOD, 2 months</td>
</tr>
<tr>
<td>2</td>
<td>73/M</td>
<td>Incidental, family history RCC</td>
<td>Oncocytoma vs RCC</td>
<td>R</td>
<td>Inferior</td>
<td>7</td>
<td>Papillary RCC</td>
<td>Yes (partial nephrectomy)</td>
<td>RCC</td>
<td>NED, 2 years</td>
</tr>
<tr>
<td>3</td>
<td>73/M</td>
<td>Incidental, family history RCC</td>
<td>Oncocytoma vs RCC</td>
<td>L</td>
<td>Inferior</td>
<td>10</td>
<td>Papillary RCC</td>
<td>Yes (partial nephrectomy)</td>
<td>RCC</td>
<td>NED, 2 years</td>
</tr>
<tr>
<td>4</td>
<td>53/M</td>
<td>Incidental</td>
<td>Small mass</td>
<td>L</td>
<td>Mesorenal</td>
<td>1.3</td>
<td>Unavailable (biopsy not performed)</td>
<td>Yes</td>
<td>(Laparoscopic cryoablation)</td>
<td>RCC</td>
</tr>
<tr>
<td>5</td>
<td>51/M</td>
<td>Convulsion, brain metastasis + renal mass</td>
<td>Histologic diagnosis</td>
<td>R</td>
<td>Mesorenal</td>
<td>5</td>
<td>Clear cell RCC</td>
<td>No</td>
<td>-</td>
<td>DOD, 11 months</td>
</tr>
<tr>
<td>6</td>
<td>50/M</td>
<td>Macroscopic hematuria</td>
<td>Small mass</td>
<td>L</td>
<td>Mesorenal</td>
<td>1.3</td>
<td>Clear cell RCC</td>
<td>Yes (radical nephrectomy)</td>
<td>RCC</td>
<td>NED, 2.5 years</td>
</tr>
<tr>
<td>7</td>
<td>49/M</td>
<td>Macroscopic hematuria</td>
<td>Small mass</td>
<td>L</td>
<td>Superior</td>
<td>5.5</td>
<td>Clear cell RCC</td>
<td>Yes (partial nephrectomy)</td>
<td>RCC</td>
<td>NED, 3 years</td>
</tr>
<tr>
<td>8</td>
<td>67/M</td>
<td>Incidental</td>
<td>Small mass</td>
<td>L</td>
<td>Superior</td>
<td>2.6</td>
<td>Clear cell RCC</td>
<td>Yes (partial nephrectomy)</td>
<td>RCC</td>
<td>NED, 2 years</td>
</tr>
<tr>
<td>9</td>
<td>27/M</td>
<td>Abdominal mass</td>
<td>Nephroblastoma vs RCC</td>
<td>L</td>
<td>Large mass</td>
<td>8</td>
<td>Nephroblastoma</td>
<td>Yes</td>
<td>(nephrectomy)</td>
<td>Nephroblastoma</td>
</tr>
<tr>
<td>10</td>
<td>78/M</td>
<td>Abdominal pain</td>
<td>Suspicion of pulmonary cancer metastasis to kidney</td>
<td>R</td>
<td>Superior</td>
<td>6</td>
<td>Pulmonary carcinoma</td>
<td>No</td>
<td>-</td>
<td>DOD, 3 months</td>
</tr>
</tbody>
</table>

M: male; RCC: renal cell carcinoma; R: right; L: left; NED: no evidence of disease; DOD: died of disease

**DISCUSSION**

More than 200,000 new cases of kidney cancer are diagnosed annually, with more than 100,000 related deaths per year worldwide. RCC accounts for 3% of all adult malignancies and is increasing at a rate of 2.5% per year.

An enhancing renal neoplasm on CT or MRI has been considered by most urologists to be a sufficient indication for surgery because about 80% of such lesions prove to be RCC. Currently, if local experience is sufficient and the biopsy result has the potential to impact treatment decisions, urologists should consider increasing the use of core biopsy and FNA to better characterize suspicious renal masses preoperatively. The advantages of a biopsy in these cases are the potential to decrease unnecessary treatment of small renal masses and better selection of tumors for active surveillance and minimally invasive ablative therapies.

The role of needle core biopsy and FNA of renal masses is primarily to rule out non renal cell primary tumors (metastasis and lymphoma) or benign conditions (abscess), which may not require surgery. Biopsy has also been used to confirm the diagnosis and the histological subtype of a renal primary lesion in patients with disseminated metastasis or unresectable retroperitoneal mass. In metastatic RCC, there is evidence that patients with clear cell subtype histology are more likely to benefit from adjuvant immunotherapy following cytoreductive nephrectomy. A role for biopsy in the new target therapies demonstrate different response rates with different RCC subtypes.

FNA with immunocytochemistry analysis can help distinguish between RCC and oncocytomas. Even though RCC may be present in as many as 18% of oncocytomas, a EUS FNA showing oncocytoma, might allow surveillance for a renal lesion, especially if the patient prefers conservative management.

Percutaneous renal mass biopsy must not be performed routinely for renal lesions less than 40 mm but it should be indicated for incompletely accurate renal imaging diagnosis after a full imaging evaluation. Almost in 30% of the selected patients, a surgical procedure became no mandatory after renal biopsy was low. In the current study, there were no complications reported.

Preoperative biopsy of renal masses should be indicated only in selected cases. Good results for EUS FNA of selected renal tumors were observed in this study. Our overall technical success rate of EUS-guided FNA was 90%, which is within the range previously reported.

The cause of failed procedure was due to the posterior aspect of this tumor and the smaller needle-tumor distance. In this patient, it appears to us that a computerized tomography guided posterior renal biopsy should be more appropriate. Some renal masses may...
be unsuitable for EUS-guided biopsy because of anatomical limitations. Among other reasons, these limitations are likely to restrict widespread application of this method. EUS-FNA will be best applied to central anterior renal masses. For lesions on the posterior kidney aspect close to abdominal wall, percutaneous approach is probably the best choice.

EUS FNA appears as a safe and feasible procedure with good results, minimal morbidity and a short hospital stay. Although this paper is the second largest case series of EUS FNA of renal masses in the literature and the first on a single-center, our results should be interpreted carefully, especially due to the small number of cases submitted to FNA. The most important questions pertain to the role of EUS-FNA of renal tumors and the patients most likely to benefit from the procedure.

Further research should evaluate the benefits of preoperative renal biopsy use and randomization of percutaneous, laparoscopic and echoendoscopic approach should be compared.